Valneva SE operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Valneva SE with three other
pharmaceutical manufacturers in Europe:
sales of 26.37 million Euro [US$28.94 million]
(1.70 billion Russian Rubles [US$27.29 million]
Moberg Pharma AB (publ)
based in Sweden
(285.57 million Swedish Kronor [US$32.32 million]
of which 55%
was Nalox/Kerasal Nail, Sales of prodcuts).
During the year ended December of 2015, sales at
Valneva SE were 78.36 million Euro (US$86.01 million).
increase of 112.2%
versus 2014, when the company's sales were 36.92 million Euro.
This was the third consecutive year of growth at Valneva SE.
Sales of Technologies and Services saw an increase
148.5% in 2015, from
5.07 million Euro to 12.59 million Euro.
Not all segments of Valneva SE experienced an increase in sales in 2015:
sales of Vaccine Candidates fell 4.2% to 8.69 million Euro.